Drug name
Last update: Aug 2026GS-3242+LEN
Developer(s)
Drug information
GS-3242 + lenacapavir
investigational
Small molecule
INSTI+capsid inhibitor
Not provided
Unknown
Unknown
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral, Subcutaneous, Route of administration is being determined in the clinical program
Associated long-acting platforms
Aqueous drug particle suspension, Oral solid form
Use of drug
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- To be determined
- Every 6 months
- Other/Variable/Unknown : To be determined
To be determined
Dosage
to be determined
to be determined
to be determined
Not provided
Comment & Information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients
Not provided
Not provided
Not provided
Delivery device(s)
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing